John Paulson Madrigal Pharmaceuticals, Inc. Transaction History
Paulson & Co. Inc.
- $1.47 Billion
- Q3 2024
A detailed history of John Paulson (Paulson & Co. Inc.) transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Paulson & Co. Inc. holds 2,042,000 shares of MDGL stock, worth $639 Million. This represents 29.57% of its overall portfolio holdings.
Number of Shares
2,042,000
Previous 1,850,000
10.38%
Holding current value
$639 Million
Previous $518 Million
16.39%
% of portfolio
29.57%
Previous 39.74%
Shares
6 transactions
Others Institutions Holding MDGL
# of Institutions
297Shares Held
22MCall Options Held
819KPut Options Held
640K-
Janus Henderson Group PLC London, X02.48MShares$776 Million0.28% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$635 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$624 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$618 Million4.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.83MShares$574 Million0.01% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.36B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...